Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer

  • Research Article
  • Published:
Tumor Biology

This article was retracted on 20 April 2017

Abstract

The aim of this study is to examine the microRNA (miRNA) expression of epithelial ovarian cancer (EOC) in both drug-resistant and drug-sensitive tissues and to explore the pathogenic characteristics of drug-resistant miRNAs in EOC. The samples with 10 cases of drug-resistant and drug-sensitive EOC tissue were obtained from undergoing surgical resection of ovarian cancer (OC). Total miRNAs were extracted and isolated, respectively. Hybridization was carried out on miRNA microarray chip. Real-time polymerase chain reaction (RT-PCR) was performed to confirm the difference of miRNA expression. Bioinformatic software was used to predict the possible target genes of each miRNA which expressed differently. The results indicated that four miRNAs related drug-resistance been identified, and the expression of hsa-miR-152 and hsa-miR-381 in drug-resistant OC tissue was significantly higher compared with those in drug-sensitive tissue (P < 0.01). However, expression of hsa-miR-200a-3p and hsa-miR-429 were downregulated in drug-resistant tissues (P < 0.01). The results obtained by miRNA microarrays of differential expression with hsa-miR-106b-3p, hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 were confirmed by real-time PCR. There were 62 significantly different miRNAs, including 42 significant upregulated miRNAs and 20 significant downregulated miRNAs in the drug-resistant tissue. Five databases, including Target Scan, miRanda, miRDB, PicTar5, and RNA22, were used for bioinformatics prediction. In conclusion, miRNA microarray analysis has become a fast and efficient molecular biological technology for the study of biological information. hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 may participate in the formation of drug resistance in EOC through the target genes predicted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Samrao D, Wang D, Ough F, Lin YG, Liu S, Menesses T, et al. Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol. 2012;5(6):469–74.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 2010;116(1):61–5.

    Article  CAS  PubMed  Google Scholar 

  4. Ying H, Lv J, Ying T, Yang Q, Ma Y. microRNA and transcription factor mediated regulatory network for ovarian cancer. Tumor Biol. 2013;34(5):3219–25.

    Article  CAS  Google Scholar 

  5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  6. Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011;300(1):10–9.

    Article  CAS  PubMed  Google Scholar 

  7. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini G. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.

    Article  CAS  PubMed  Google Scholar 

  9. Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW, et al. Differential microDNA expression signatures and cells type-specific associated with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 2014;8(1):293–314.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Raza U, Zhang JD, Sahin O. MicroRNA expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20(7):1990–2000.

    Article  Google Scholar 

  11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–8.

    Article  CAS  PubMed  Google Scholar 

  12. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207–25.

    Article  CAS  PubMed  Google Scholar 

  13. Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. miRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumor Biol. 2013;34(6):3501–8.

    Article  CAS  Google Scholar 

  14. Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumor Biol. 2011;32(5):1031–47.

    Article  CAS  Google Scholar 

  15. Burchenal JH, Robinson E, Johnston SF, Kushida MN. The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia. Science. 1950;111(2875):116.

    Article  CAS  PubMed  Google Scholar 

  16. Boren T, Xiong Y, Hakam A, Wwnham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009;113(2):249–55.

    Article  CAS  PubMed  Google Scholar 

  17. Ying H, Lv J, Ying T, Li J, Yang Q, Ma Y. microRNA and transcription factor mediated regulatory network for ovarian cancer. Tumor Biol. 2013;34(5):3219–25.

    Article  CAS  Google Scholar 

  18. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012;11(12):2556–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sun C, Li N, Zhou B, Yang Z, Ding D, Weng D, et al. miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1. Oncol Lett. 2013;6(2):507–12.

    PubMed  PubMed Central  Google Scholar 

  20. Li H, Xu H, Shen H, Li H. microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett. 2014;7(1):7183–8.

    Google Scholar 

  21. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by National High Technology Research and Development Program of China (No. 012AA02A507), and the Research Fund for the Doctoral Program of Higher Education of China (No. 20134503110009).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Gynecology Oncology, Affiliated Tumor Hospital, Guangxi Medical University, Nanning, 530021, Guangxi, China

    Ling Liu, Jing Zou, Qi Wang, Wei Zhang & Li Li

  2. Medical Scientific Research Center, Guangxi Medical University, Nanning, 530021, Guangxi, China

    Fu-Qiang Yin

Authors
  1. Ling Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fu-Qiang Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Li.

Additional information

Ling Liu and Jing Zou contributed equally to the present study.

The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.

An erratum to this article can be found online at http://dx.doi.org/10.1007/s13277-017-5487-6.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, L., Zou, J., Wang, Q. et al. RETRACTED ARTICLE: Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer. Tumor Biol. 35, 7713–7717 (2014). https://doi.org/10.1007/s13277-014-1970-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1970-5

Keywords

Search

Navigation